Therapeutic Drug Monitoring
April 1, 2002
Manfred R. Moeller, Thomas Kraemer
98 citations
Driving under the influence of drugs is a growing concern in industrialized countries, contributing to road accidents. In forensic toxicology, the increasing number of blood samples for drug testing results from zero-tolerance laws and better-trained police officers. This review describes procedures for detecting amphetamine, methamphetamine, MDMA, MDEA, MDA, cannabinoids (THC and its metabolites), cocaine and its metabolites, opiates (heroin, 6-monoacetylmorphine, morphine, codeine), methadone, GHB, LSD, PCP, and psilocybin/psilocin in whole blood, plasma, and serum. Sensitive immunologic screening methods are available for many analytes. Gas chromatography-mass spectrometry remains the gold standard for confirmatory analysis, with liquid chromatography-mass spectrometry also included. Two tables summarize basic data on biosample, internal standard, workup, column, mobile phase, detection mode, and validation.
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology
October 1, 2017
Michael D Wunderli, Matthias Vonmoos, Marina Fürst et al.
37 citations
Chronic MDMA use is linked to memory and thinking problems, but past research often failed to separate effects of MDMA from those of other drugs like stimulants. In this study, 26 MDMA users who avoided stimulants, 25 MDMA users who also used stimulants, and 56 non-users completed cognitive tests. Hair analysis confirmed drug use patterns. MDMA-only users showed strong, specific impairments in declarative memory (effect size d=0.90), while stimulant-using MDMA users had broader, larger deficits across memory, working memory, executive functions, and attention (d=0.70 to 1.21). The findings suggest that pure MDMA use mainly harms declarative memory, whereas additional cognitive deficits stem from stimulant co-use.
Frontiers in pharmacology
January 1, 2023
Dario A Dornbierer, Laurenz Marten, Jovin Mueller et al.
32 citations
Ayahuasca, an Amazonian plant medicine containing DMT and harmine, shows promise for mental health disorders but its oral use causes gastrointestinal side effects and unpredictable drug levels. This study tested new ayahuasca-analogue formulations in 10 healthy men: an oral capsule of purified DMT and harmine versus a combined oromucosal harmine tablet with intranasal DMT spray. The combined buccal/intranasal route significantly reduced variations in systemic exposure and attenuated common side effects like nausea, vomiting, and diarrhea compared to traditional oral ayahuasca. All preparations were well tolerated. This approach may enable safer, patient-friendly DMT/harmine administration for affective disorders.
PLoS ONE
June 15, 2016
Andrea E Steuer, Corina Schmidhauser, Eva H Tingelhoff et al.
18 citations
Bupropion pretreatment increased the maximum plasma concentration and overall exposure of both MDMA stereoisomers, while reducing the levels of its major metabolites by about 40%, in healthy volunteers. These changes in MDMA pharmacokinetics due to reduced CYP2D6 activity were similar to those seen in people with naturally lower CYP2D6 function (intermediate metabolizers). The alterations in stereoselectivity based on CYP2D6 activity likely have low clinical relevance. Bupropion and its metabolite levels were not affected by MDMA co-administration.